Athenex to Participate in the 5th Annual Evercore ISI HealthCONx Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Athenex (NASDAQ: ATNX), a biopharmaceutical company focused on cancer therapies, will participate in the 5th Annual Evercore ISI HealthCONx Conference from November 29 to December 1, 2022. Management, including CEO Dr. Johnson Lau and President Dr. Dan Lang, will engage in a fireside chat on November 30 at 3:05 PM ET. Additionally, they will hold one-on-one investor meetings, available upon scheduling through Evercore ISI representatives. Athenex aims to advance next-generation cell therapy and improve cancer treatment outcomes.
Details
News Market Reaction – ATNX
The recorded move for ATNX in the trading session of this news was -3.21%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BUFFALO, N.Y., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that management will participate in the 5th Annual Evercore ISI HealthCONx Conference, taking place virtually November 29 to December 1, 2022.
Dr. Johnson Lau, Chief Executive Officer of Athenex, and Dr. Dan Lang, President of Athenex Cell Therapy, will be participating in a fireside chat on Wednesday, November 30, 2022, beginning at 3:05pm Eastern Time. Athenex management will also be available for one-on-one investor meetings during the event. Please contact your representative at Evercore ISI to schedule a virtual one-on-one meeting with management during the conference.
About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical-stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation cell therapy drugs for the treatment of cancer. In pursuit of this mission, Athenex leverages years of experience in research and development, clinical trials, regulatory standards, and manufacturing. The Company’s current clinical pipeline is derived mainly from the following core technologies: (1) Cell therapy, based on NKT cells and (2) Orascovery, based on a P-glycoprotein inhibitor. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active, accessible, and tolerable treatments. For more information, please visit www.athenex.com.
Athenex Contacts
Daniel Lang, M.D.
Athenex, Inc.
Email: danlang@athenex.com
Tim McCarthy
LifeSci Advisors, LLC
Email: tim@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.